参考文献

参考文献

［1］Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA：a cancer journal for clinicians，2018，68（6）：394-424.

［2］Quint LE，Tummala S，Brisson LJ，et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer［J］.Ann Thorac Surg，1996，62（1）：246-250.

［3］Ileana E，Greillier L，Moutardier V，Barlesi F.Surgical resection of liver non-small cell lung cancer metastasis：a dual weapon？［J］.Lung Cancer，2010，70（2）：221-222.

［4］Nagashima A，Abe Y，Yamada S，et al.Long-term survival after surgical resection of liver metastasis from lung cancer［J］.Jpn J Thorac Cardiovasc Surg，2004，52（6）：311-313.

［5］Wang S，Wei YD，Zhao Z，et al.Risk factors of liver metastasis in non-small cell lung cancer and comparison of different therapies［J］.Chinese Journal of Disease Control，2016，20（9）：936-939.

［6］Chen L，Huang P，Zhang XJ，et al.Efficacy and safety evaluation of irinotecan plus lobaplatin in patients with small cell lung cancer liver metastases who failed chemotherapy with etoposide regimen［J］.Hebei Medicine，2016，38（20）：3098-3100.

［7］Zhang CS，Liu XL.Therapeutic effect of intravenous chemotherapy combined with percutaneous ethanol injection for hepatic metastasis［J］.Modern Oncology，2016，24（18）：2906-2909.

［8］Milano MT，Katz AW，Schell MC，et al.Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy［J］.Int JRadiat Oncol Biol Phys，2008，72（5）：1516-1522.

［9］Kanthi，Rekha，Badipatla，et al. Lung cancer metastasis to the gastrointestinal system：An enigmatic occurrence［J］.World Journal of Gastrointestinal Oncology，2017，9（3）：129-134.

［10］Shaverdian N，Lisberg AE，Bornazyan K，et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer：A secondary analysis of the KEYNOTE-001 phase 1 trial［J］.Lancet Oncol，2017，18：895-903.

［11］Lin SZ，Xu Qian，Wu JY，et al.Ultrasound—guided percutaneous radiofrequency ablation for malignant liver metastases［J］. Chinese Journal of Interventional Imaging and Therapy，2018，15（1）：29-32.

［12］Tseng SE，Chiou YY，Lee YC，et al.Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases［J］.Lung Cancer，2014，86（2）：225-230.(https://www.daowen.com)

［13］Shibata T，Niinobu T，Ogata N，et al.Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma［J］.Cancer，2000，89（2）：276-284.

［14］Ai DM，Xu JX，Liu CJ，et al.Microwave ablation treatment of liver metastatic carcinoma clinical efficacy and related factors affecting survival rate［J］.Cancer Progression，2017，15（6）：667-669.

［15］Liu XZ，Li H，Wang X，et al. Clinical value of hepatic arterial chemoembolization combined with percutaneous microwave ablation for liver metastasis of lung cancer［J］.Medical Equipment，2016，29（14）：16-17.

［16］Xue MY，Zhou ZM.Therapeutic effect and safety of dual interventional treatment for lung cancer with hepatic metastasis［J］. Chinese Hepatology，2017，22（11）：1038-1041.

［17］Tseng SE，Chiou YY，Lee YC，et al.Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases［J］.Lung Cancer，2014，86（2）：225-230.

［18］Castanon E，Rolfo C，Vinal D，et al.Impact of epidermal growth factor receptor （EGFR） activating mutations and their targeted treatment in the prognosis of stageⅣnon-small cell lung cancer（NSCLC） patients harboring liver metastasis［J］. Journal of Translational Medicine，2015，13（1）：257.

［19］Zhu ZY，Chai Y.Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib［J］.Thoracic Cancer，2016，7（6）：681-683.

［20］Liu XL，Ji W，Li L，et al.Treatment of lung adenocarcinoma with erlotinib hydrochloride tablets，post-drug chemotherapy and bevacizumab injection：a case report and review of literature［J］.Journal of Jilin University（Medicine Edition），2017，43（5）：1019-1024.

［21］Tournoy KG，Thomeer M，GermonpréP，et al.Does nivolumab for progressed metastatic lung cancer fulfill its promises？An efficacy and safety analysis in 20 general hospitals［J］.Lung Cancer，2018，115：49-55.

［22］Ricciuti B，Metro G，Baglivo S，et al. Long lasting response to nivolumab and immune related adverse events in a nonsquamous metastatic non-small cell lung cancer patient［J］.Journal of Thoracic Oncology，2017，12（5）：51-55.

［23］Vokes EE，Ready E，Felip E，et al.Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer（CheckMate 017 and CheckMate 057）：3-year update and outcomes in patients with liver metastases［J］.Annals of Oncology，2018，44（1）：12-21.

［24］Funazo T，Nomizo T，Kim YH.Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab［J］.Thorac Oncol，2017，12（9）：140-141.